Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Moderna Starts Dosing In Mid-Stage Omicron-Specific Bivalent Booster Candidate

Moderna Inc (NASDAQ:MRNA) has dosed the first participant in the Phase 2 study of its omicron-specific bivalent booster candidate (mRNA-1273.214).

The vaccine candidate combines Moderna's omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273).

The extension of an earlier study will evaluate mRNA-1273.214 as a single booster dose in adults who previously received the two-dose primary series of mRNA-1273 and a 50 µg booster dose of mRNA-1273 with the booster dose being at least three months ago. 

Also See: Moderna Plans Vaccines Against 15 Pathogens With Future Pandemic Potential.

Moderna expects to enroll approximately 375 participants.

The Company is also evaluating its omicron-specific booster candidate (mRNA-1273.529) in a Phase 2 study in the U.S. 

Separately, Moderna is evaluating mRNA-1273.529 in a Phase 3 study in the U.K., collaborating with the National Institute for Health Research. Dosing with mRNA-1273.214 will begin soon.

Price Action: MRNA shares are down 3.53% at $137.46 during the market session on the last check Thursday.

Photo by mufidpwt via Pixaby

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.